Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629759 | 0.83 | TDP1 (0.57) | LMNAMTNR1AMTNR1BTDP1GPR88 | |
| SCHEMBL28821943 | 0.80 | LMNA (0.47) | LMNAMTNR1AMTNR1BTDP1GPR88 | |
| SCHEMBL4550642 | 0.77 | ALOX5 (0.53) | LMNAMTNR1AMTNR1BTDP1ALOX5 | |
| SCHEMBL3966237 | 0.76 | ALOX5 (0.49) | LMNAMTNR1AMTNR1BTDP1ALOX5 | |
| SCHEMBL11052073 | 0.76 | LMNA (0.53) | LMNAMTNR1AMTNR1BTDP1ALOX15 | |
| SCHEMBL5515375 | 0.74 | TDP1 (0.59) | TDP1ALOX5PPARGPPARA | |
| SCHEMBL6032899 | 0.74 | LMNA (0.60) | LMNA | |
| SCHEMBL5819286 | 0.74 | PLA2G4B (0.47) | MTNR1AMTNR1BTDP1 | |
| SCHEMBL7914370 | 0.73 | HDAC1 (0.54) | LMNATDP1PPARGPPARA | |
| Ethane SCHEMBL5531789 | 0.72 | LMNA (0.49) | LMNAMTNR1AMTNR1BTDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2493932-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056423-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | ALOX12, THEM6, ALOX15 | LMNA 4232/4885MTNR1A 4152/4885MTNR1B 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.